conduct
retrospect
cohort
studi
outpati
age
year
present
care
seattl
cancer
care
allianc
scca
intern
classif
diseas
tenth
revis
clinic
modif
code
consist
acut
uri
acut
bronchiti
supplementari
method
octob
septemb
outpati
care
scca
compris
larg
ambulatori
clinic
offsit
satellit
clinic
electron
medic
record
data
includ
patient
demograph
clinic
data
antibiot
antivir
prescript
viral
diagnost
test
obtain
chart
review
conduct
verifi
uri
diagnosi
code
identifi
index
date
first
clinic
encount
uri
day
patient
without
document
activ
uri
symptom
evid
lower
respiratori
tract
infect
lrti
day
exclud
patient
uri
studi
period
first
episod
select
analysi
captur
provid
respons
decis
make
day
patientreport
uri
symptom
start
date
classifi
antibiot
prescript
day
urirel
steroid
use
immunosuppress
medic
chemotherapi
record
clinic
outcom
day
collect
includ
healthcar
visit
hospit
clinic
andor
radiograph
evid
lrti
fred
hutch
institut
review
board
approv
studi
lrti
defin
clinic
sign
symptom
respiratori
tract
infect
pulmonari
infiltr
radiograph
imag
compat
bacteri
viral
pneumonia
eg
consolid
interstiti
infiltr
groundglass
opac
healthcar
visit
hospit
classifi
urirel
uri
symptom
address
encount
regardless
primari
reason
encount
peak
flu
season
defin
decemb
march
nasal
swab
submit
respiratori
viral
test
clinician
discret
test
gener
perform
use
laboratorydevelop
multiplex
polymeras
chain
reaction
pcr
test
detect
respiratori
virus
addit
test
includ
biofir
filmarray
respiratori
panel
influenzaspecif
test
cepheid
xpert
flu
also
captur
clostridioid
difficil
test
perform
use
pcr
xpert
c
difficil
cepheid
patient
first
antibiot
antivir
prescript
indic
uri
first
viral
diagnost
test
day
select
main
analys
poisson
gener
estim
equat
gee
regress
model
use
test
associ
baselin
factor
risk
antibiot
prescrib
uri
day
poisson
model
chosen
provid
rel
risk
rr
model
estim
gee
use
account
correl
among
patient
seen
provid
candid
explanatori
variabl
chosen
priori
base
factor
previous
identifi
import
antibiot
prescrib
uri
gener
popul
factor
specif
cancer
popul
limit
candid
variabl
ensur
minimum
approxim
event
per
covari
variabl
includ
viral
test
perform
day
clinic
servic
peak
flu
season
patient
age
symptom
present
comorbid
steroid
immunosuppress
medic
week
day
chemotherapi
day
day
symptom
present
defin
use
follow
mutual
exclus
categori
fever
fever
either
sputum
product
chest
congest
respiratori
viral
symptom
absenc
fever
sputum
product
chest
congest
first
ran
univari
model
construct
parsimoni
multivari
model
use
purpos
variabl
select
approach
supplementari
method
viral
test
clinic
servic
highli
relat
consid
variabl
separ
model
poisson
regress
robust
standard
error
use
compar
binari
outcom
urirel
healthcar
visit
day
patient
without
antibiot
prescript
day
patient
consid
independ
outcom
sa
version
sa
institut
cari
nc
use
analys
patient
select
chart
review
base
diagnosi
code
exclud
mostli
due
lack
document
uri
symptom
present
figur
patient
seen
provid
elig
analysi
baselin
characterist
shown
tabl
patient
hematolog
malign
disord
howev
seen
satellit
clinic
solid
tumor
malign
cough
nasal
congest
commonli
report
present
symptom
approxim
onequart
patient
present
care
within
day
symptom
onset
within
day
wait
longer
week
seek
care
time
symptom
onset
day
unknown
patient
elig
patient
prescrib
antibiot
uri
symptom
prescript
order
day
day
day
patient
prescrib
antibiot
receiv
first
prescript
visit
worsen
uri
symptom
lrti
addit
patient
receiv
antibiot
presum
bacteri
sinus
azithromycin
fluoroquinolon
commonli
prescrib
antibiot
supplementari
figur
antibiot
prescrib
vari
provid
figur
one
provid
saw
patient
uri
prescrib
antibiot
patient
patient
seen
provid
exclud
antibiot
prescrib
rate
entir
cohort
antibiot
prescrib
also
vari
clinic
servic
least
use
among
patient
manag
bone
marrow
transplant
bmt
servic
use
among
patient
visit
satellit
clinic
figur
p
twentysix
patient
prescrib
antivir
oseltamivir
given
case
ribavirin
prescrib
patient
contrast
antibiot
antivir
less
like
prescrib
day
often
prescrib
day
remain
patient
prescrib
day
patient
prescrib
antivir
also
prescrib
antibiot
prescrib
drug
day
prescrib
antivir
antibiot
viral
test
perform
among
patient
test
use
local
multiplex
pcr
test
use
fluspecif
test
use
biofir
filmarray
test
test
frequent
done
bmt
team
follow
hematolog
servic
rare
among
solid
tumor
servic
satellit
clinic
figur
p
respiratori
viral
test
usual
perform
day
test
result
avail
day
test
perform
patient
day
later
day
later
case
among
test
least
viru
detect
rhinoviru
influenza
coronaviru
commonli
detect
virus
figur
patient
viral
test
perform
day
less
like
receiv
antibiot
prescript
day
compar
without
viral
test
day
p
howev
among
subset
patient
test
day
without
antibiot
prescrib
test
result
avail
percentag
patient
receiv
antibiot
prescript
test
result
date
vari
test
result
p
shown
tabl
antivir
alway
prescrib
follow
posit
test
influenza
rare
prescrib
follow
nonflu
posit
neg
test
p
univari
analysi
viral
test
day
associ
less
half
risk
antibiot
prescrib
compar
test
day
supplementari
figur
nonbmt
clinic
servic
older
age
sputum
product
congest
associ
increas
risk
antibiot
prescrib
uri
due
collinear
relationship
viral
test
clinic
servic
multivari
model
antibiot
use
gener
model
includ
viral
test
rather
clinic
servic
potenti
factor
viral
test
symptom
sputum
product
chest
congest
remain
significantli
associ
antibiot
prescrib
rel
risk
similar
unadjust
estim
age
longer
statist
signific
figur
separ
model
includ
clinic
servic
rather
viral
test
candid
variabl
clinic
servic
symptom
present
remain
significantli
associ
antibiot
prescrib
age
reach
threshold
inclus
model
rel
risk
estim
similar
unadjust
estim
though
fever
reach
statist
signific
model
though
patient
chest
x
ray
comput
tomographi
scan
followup
period
develop
evid
lrti
one
patient
autolog
hct
day
uri
progress
upper
lower
respiratori
tract
respiratori
syncyti
viru
infect
patient
radiograph
clinic
concern
bacteri
pneumonia
two
patient
test
posit
c
difficil
within
day
day
neither
receiv
antibiot
uri
within
day
initi
uri
encount
patient
least
clinic
visit
emerg
depart
visit
hospit
admiss
total
healthcar
visit
visit
consid
urirel
supplementari
tabl
healthcar
visit
common
among
bmt
patient
supplementari
figur
receipt
antibiot
prescript
day
associ
risk
urirel
followup
visit
day
model
adjust
age
clinic
servic
comorbid
immunosuppress
medic
previou
week
chemotherapi
previou
day
rr
confid
interv
p
knowledg
first
describ
antibiot
prescrib
pattern
acut
uri
ambulatori
oncolog
set
found
nearli
patient
receiv
antibiot
prescript
uri
diagnosi
antibiot
prescrib
vari
substanti
clinic
servic
significantli
less
common
among
patient
multiplex
respiratori
viral
test
perform
though
collinear
clinic
servic
viral
test
limit
abil
separ
effect
prescrib
find
similar
report
nation
survey
estim
antibiot
prescrib
outpati
visit
viral
uri
includ
respiratori
diagnos
antibiot
would
gener
consid
inappropri
accord
nation
guidelin
multiplex
respiratori
viral
test
nearli
half
patient
support
viral
etiolog
among
major
test
antibiot
ineffect
furthermor
demonstr
adjust
analysi
urirel
followup
visit
subsequ
week
significantli
differ
among
patient
prescrib
antibiot
initi
encount
compar
seriou
outcom
relat
uri
lrti
hospit
rare
found
antibiot
prescrib
significantli
less
common
patient
receiv
respiratori
viral
test
viral
test
also
influenc
oseltamivir
prescrib
studi
evalu
effect
respiratori
viral
molecular
diagnost
test
antibiot
prescrib
outpati
set
recent
larg
studi
outpati
acut
respiratori
infect
found
patient
clinic
diagnosi
code
influenza
decreas
odd
receiv
antibiot
prescript
howev
studi
onequart
patient
research
influenza
receiv
clinic
diagnosi
code
influenza
antibiot
prescrib
patient
research
influenza
suggest
improv
access
rapid
molecular
diagnost
may
help
reduc
antibiot
prescrib
openlabel
random
control
trial
found
access
multiplex
respiratori
viral
pcr
reduc
antibiot
prescrib
initi
outpati
visit
although
effect
sustain
followup
visit
day
later
retrospect
studi
patient
veteran
administr
medic
center
found
fewer
antibiot
prescript
among
patient
test
posit
influenza
ondemand
biofir
filmarray
respiratori
panel
differ
antibiot
prescrib
patient
noninfluenza
respiratori
viru
patient
respiratori
viru
detect
though
observ
significantli
lower
rate
antibiot
prescrib
among
patient
receiv
respiratori
viral
test
antibiot
prescrib
vari
test
result
small
sampl
size
may
limit
abil
detect
differ
test
result
other
describ
possibl
access
viral
test
along
prospect
achiev
diagnosi
could
influenc
prescrib
behavior
viral
test
may
also
fulfil
provid
desir
meet
perceiv
patient
expect
intervent
manag
uri
turnaround
time
tat
test
result
hour
unknown
whether
rapid
tat
avail
pointofcar
test
could
impact
prescrib
final
provid
may
prescrib
antibiot
despit
posit
respiratori
viru
test
due
concern
bacteri
coinfect
among
vulner
patient
popul
practic
viral
test
highli
correl
clinic
servic
difficult
know
whether
lower
rate
antibiot
prescrib
among
patient
receiv
viral
test
attribut
test
due
servicespecif
cultur
differ
provid
prescrib
behavior
interestingli
antibiot
prescrib
lowest
among
bmt
patient
often
consid
among
highest
risk
howev
patient
seen
clinic
frequent
patient
provid
may
felt
comfort
defer
antibiot
due
closer
followup
highest
rate
antibiot
prescrib
observ
satellit
clinic
manag
mix
patient
solid
tumor
hematolog
malign
clinic
well
sever
highvolum
prescrib
identifi
present
opportun
antimicrobi
stewardship
program
outreach
consider
strategi
previous
describ
includ
peer
comparison
examin
specif
provid
factor
beyond
clinic
servic
howev
previou
studi
found
physician
specialti
age
level
career
gender
patient
volum
countri
train
associ
antibiot
prescrib
uri
consist
previou
studi
patient
present
symptom
sputum
product
chest
congest
like
receiv
antibiot
prescript
also
found
weak
associ
fever
similar
studi
demonstr
associ
magnitud
gener
lower
sputum
product
although
antibiot
prescrib
may
warrant
case
symptom
present
result
identifi
opportun
clarifi
nuanc
clinic
present
target
educ
studi
sever
limit
first
result
may
generaliz
set
outpati
viral
diagnost
test
may
readili
avail
variat
physician
cultur
across
clinic
servic
may
differ
high
correl
observ
clinic
servic
viral
diagnost
test
limit
abil
separ
effect
antibiot
prescrib
may
also
uniqu
institut
viral
test
occur
within
bmt
hematolog
servic
difficult
draw
conclus
role
viral
test
antibiot
prescrib
among
solid
tumor
patient
second
modest
sampl
size
limit
abil
evalu
addit
factor
associ
antibiot
prescrib
howev
smaller
sampl
size
enabl
us
address
limit
bill
data
perform
detail
chart
review
verifi
diagnosi
code
notabl
nearli
patient
code
consist
uri
chart
document
uri
symptom
larger
studi
reli
diagnosi
code
bill
data
may
unabl
account
discrep
final
formal
review
antibiot
prescript
uri
assess
appropri
howev
chose
diagnosi
code
correspond
condit
antibiot
would
gener
consid
inappropri
consist
approach
taken
studi
addit
review
diagnos
sinus
found
appropri
use
case
contribut
minim
total
antibiot
use
cohort
conclus
found
nearli
patient
seen
ambulatori
cancer
center
prescrib
antibiot
uri
viral
etiolog
identifi
major
patient
test
test
associ
decreas
antibiot
usag
antibiot
prescript
link
subsequ
urirel
healthcar
visit
find
highlight
need
research
explor
role
costeffect
molecular
respiratori
viral
test
limit
unnecessari
antibiot
use
among
patient
